CME Sponsor:
Imedex

Location:
New York Marriott at the Brooklyn Bridge
Brooklyn, New York

Course Directors/Instructors:
Richard T. Silver, MD, FACP
Chair
Weill Cornell Medical College
NewYork-Presbyterian Hospital/
Weill Cornell Medical Center

Jerry L. Spivak, MD, FACP
Co-Chair
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Wallace Akerley, MD
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
Hershey, Pennsylvania

Jeffrey D. Bradley, MD
Washington University School of Medicine
St. Louis, Missouri

Jessica S. Donington, MD, MSCR
New York University School of Medicine
New York, New York

David S. Ettinger, MD, FACP, FCCP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Tracey L. Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Barbara Gitlitz, MD
University of Southern California
Keck School of Medicine
Los Angeles, California

Ramaswamy Govindan, MD
Washington University School of Medicine
St. Louis, Missouri

Nasser H. Hanna, MD
Indiana University
Indianapolis, Indiana
 
Daniel D. Karp, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

Rogerio C. Lilenbaum, MD
Cleveland Clinic Florida
Weston, Florida

R. Nevin Murray, MD, FRCPC
British Columbia Cancer Agency
Vancouver, BC, Canada

Suresh S. Ramalingam, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

Charles M. Rudin, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center
John Hopkins University
Baltimore, Maryland

Howard Safran, MD
Brown University Oncology Group
Providance, Rhode Island

Beth Eaby Sandy, CRNP
University of Pennsylvania
Philadelphia, Pennsylvania

Mitchell Schnall, MD, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Lecia V. Sequist, MD, MPH
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

 Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

Anne S. Tsao, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Maria Werner-Wasik, MD
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Number of Credits:
AMA PRA Category 1 Credit™, amount TBA

Registration Fee:
Discounted (payment received by 9/1/11) $325.00
Regular (payment received by 10/27/11) $425.00
Full/Onsite (payment received after 10/27/11) $525.00
Group discount (physicians only, cannot be combined with other discounts) -$50.00
Nurses/Residents/Students (proof of eligibility must accompany registration, cannot be combined with other discounts) $199.00

You may register online by November 10, 2011 or by phone at 1-855-276-6855. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

For easy registration or any questions, please call toll free at 1-855-276-6855.

Link

Brochure

Detailed Description:
This educational activity is specifically designed for hematologists, internists, oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) interested and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.

Since the inaugural Congress in 2001, this has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. The focus will be on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofi brosis, chronic myeloid leukemia and myelodysplasia.

Learning Objectives:
After completion of this educational activity, participants should be able to:
-    Review the classification and pathogenesis of myelodysplastic diseases
-    Discuss current best practices in the treatment of MDS
-    Comment on novel drugs in MDS, with a focus on management of iron overload
-    Review new prognostic classifications and their relevance to allogeneic transplantation in primary myelofibrosis
-    Discuss novel markers and therapies beyond JAK2 in myelofi brosis
-    Review important genetic abnormalities in myeloproliferative disorders
-    Comment on the clinical significance of mutations in polycythemia vera
-    Identify the importance of cerebral circulation in outcomes related to polycythemia vera
-    Discuss molecular drug targets in myeloproliferative disorders
-    Review risk factors for thrombosis in MPDs
-    Review the most current updates in the biology and pathogenesis of CML
-    Improve response monitoring and overcome drug resistance to improve CML outcomes
-    Review the management of CML in pregnancy
-    Discuss second and third generation tyrosine kinase inhibitors and their current and future positioning within the current treatment armamentarium
-    Review treatment of accelerated and blast phase CML disease
-    Debate the optimal role of transplantation in CML